New hope for aggressive brain tumors: avastin delivered directly to the brain

NCT ID NCT01269853

Recruiting now Disease control Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving the drug bevacizumab (Avastin) directly into the brain's arteries, repeated over time, is safe and effective for people with recurrent glioblastoma or anaplastic astrocytoma. The approach uses a special infusion to bypass the blood-brain barrier. About 54 adults with these aggressive brain tumors will be enrolled to see if this method improves survival compared to standard intravenous delivery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin)
What this could lead to: If it works, this could offer a new way to deliver bevacizumab directly to brain tumors, potentially improving survival for patients with recurrent glioblastoma or anaplastic astrocytoma.
What could go wrong: This is an early phase 1/2 trial with only 54 participants, so results may not apply broadly. The treatment involves a procedure to open the blood-brain barrier, which carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic astrocytoma anaplastic oligoastrocytoma astrocytoma (excluding glioblastoma) glioblastoma glioma susceptibility 1 neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC ASTROCYTOMA GLIOBLASTOMA MULTIFORME

Contacts and locations

Locations

Lenox Hill Brain Tumor Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.